In 2018, a phase 3 clinical trial showed that olaparib, a potent PARP inhibitor, dramatically improved the disease-free survival of ovarian cancer patients carrying the breast cancer type susceptibility protein 1/2 (BRCA1/2) mutation by 70% (3 years) compared with the placebo [109,110]. Here, BRCA1 is linked to ovarian carcinoma.